細胞性腫瘍抗原p53治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Cellular Tumor Antigen p53 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0410
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:134
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Cellular Tumor Antigen p53 – Pipeline Review, H2 2019
Summary

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The latest report Cellular Tumor Antigen p53 – Pipeline Review, H2 2019, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 7, 2, 7, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology and Toxicology which include indications Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Solid Tumor, Esophageal Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Pancreatic Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Blood Cancer, Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chemotherapy Effects, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Delayed Graft Function (DGF), Endometrial Cancer, Gastrointestinal Tumor, Gliosarcoma, Hepatic – Colorectal Metastasis, Hepatocellular Carcinoma, Leukemia, Li-Fraumeni Syndrome (LFS), Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Soft Tissue Sarcoma and Urinary Tract Cancer.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
- The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Overview
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Companies Involved in Therapeutics Development
Actavalon Inc
ADRx Inc
Affina Biotechnologies Inc
Aprea Therapeutics AB
BlinkBio Inc
CanBas Co Ltd
Cotinga Pharmaceuticals Inc
Innovation Pharmaceuticals Inc
ISA Pharmaceuticals BV
LynkCell Inc
MultiVir Inc
ORCA Therapeutics BV
OSE Immunotherapeutics
Pharos I&BT Co Ltd
PMV Pharmaceuticals Inc
Quark Pharmaceuticals Inc
Shenzen SiBiono GeneTech Co Ltd
SynerGene Therapeutics Inc
Tara Immuno-Oncology Therapeutics LLC
Z53 Therapeutics LLC
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Drug Profiles
Adp-53DCV – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APR-246 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APR-548 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AU-14022 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contusugene ladenovec – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Dormant Products
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Discontinued Products
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Actavalon Inc, H2 2019
Pipeline by ADRx Inc, H2 2019
Pipeline by Affina Biotechnologies Inc, H2 2019
Pipeline by Aprea Therapeutics AB, H2 2019
Pipeline by BlinkBio Inc, H2 2019
Pipeline by CanBas Co Ltd, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Innovation Pharmaceuticals Inc, H2 2019
Pipeline by ISA Pharmaceuticals BV, H2 2019
Pipeline by LynkCell Inc, H2 2019
Pipeline by MultiVir Inc, H2 2019
Pipeline by ORCA Therapeutics BV, H2 2019
Pipeline by OSE Immunotherapeutics, H2 2019
Pipeline by Pharos I&BT Co Ltd, H2 2019
Pipeline by PMV Pharmaceuticals Inc, H2 2019
Pipeline by Quark Pharmaceuticals Inc, H2 2019
Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2019
Pipeline by SynerGene Therapeutics Inc, H2 2019
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2019
Pipeline by Z53 Therapeutics LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Actavalon Inc
ADRx Inc
Affina Biotechnologies Inc
Aprea Therapeutics AB
BlinkBio Inc
CanBas Co Ltd
Cotinga Pharmaceuticals Inc
Innovation Pharmaceuticals Inc
ISA Pharmaceuticals BV
LynkCell Inc
MultiVir Inc
ORCA Therapeutics BV
OSE Immunotherapeutics
Pharos I&BT Co Ltd
PMV Pharmaceuticals Inc
Quark Pharmaceuticals Inc
Shenzen SiBiono GeneTech Co Ltd
SynerGene Therapeutics Inc
Tara Immuno-Oncology Therapeutics LLC
Z53 Therapeutics LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[細胞性腫瘍抗原p53治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆